

Infliximab (Remicade®, Inflectra®, Renflexis®, Avsola™, Infliximab)

When requesting an infliximab product (Remicade, Inflectra, Renflexis, Avsola, Infliximab) for non-oncology indications, the individual requiring treatment must be diagnosed with an FDA-approved indication or approved off-label compendial use and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indications

Infliximab is indicated for the treatment of:

- Crohn's disease
- Ulcerative colitis
- Rheumatoid arthritis
- Psoriatic arthritis
- Plaque psoriasis
- Ankylosing spondylitis

Approved Off-label Compendial Uses

- Behcet's disease
- Graft-versus-host disease
- Hidradenitis suppurativa
- Colitis, indeterminate
- Juvenile idiopathic arthritis
- Pyoderma gangrenosum
- Sarcoidosis
- Scleritis or sterile corneal ulceration
- Still's disease
- Spondyloarthritis, other subtypes
- Uveitis
- Immunotherapy-related toxicities associated with checkpoint inhibitor therapy

Coverage Guidelines

Rheumatoid arthritis (RA)

The individual must meet both of the following criteria for initial authorization:

- Had a 3-month trial of at least one biologic agent or at least one conventional synthetic disease-modifying antirheumatic drug (DMARD);
- Infliximab is prescribed by or in consultation with a rheumatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Clinical Disease Activity Index [CDAI], Patient Activity Scale [PAS]-II, Rapid Assessment of Patient Index Data 3 [RAPID-3], etc.); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints, etc.).

Ankylosing spondylitis (AS)

The individual must meet the following criteria for initial authorization:

- Infliximab is prescribed by or in consultation with a rheumatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Ankylosing Spondylitis Disease Activity Score [ASDAS], Ankylosing Spondylitis Quality of Life Scale [ASQoL], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], serum markers [e.g., C-reactive protein, erythrocyte sedimentation rate], etc.); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain or stiffness; improvement in function or activities of daily living).

Psoriatic arthritis (PsA)

The individual must meet the following criteria for initial authorization:

- Infliximab is prescribed by or in consultation with a rheumatologist or a dermatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Disease Activity Index for Psoriatic

Arthritis [DAPSA], Composite Psoriatic Disease Activity Index [CPDAI], Psoriatic Arthritis Disease Activity Score [PsA DAS], Psoriatic Arthritis Impact of Disease [PsAID-12], and/or serum markers); OR

- o Has experienced an improvement in at least one symptom compared to baseline (e.g., less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints, etc.).

Crohn's disease (CD)

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Meets one of the following:
 - o Has enterocutaneous (perianal or abdominal) or rectovaginal fistulas;
 - o Had ileocolonic resection;
 - o Has tried one other systemic agent for Crohn's disease (e.g., certolizumab, adalimumab, vedolizumab, ustekinumab, methotrexate, 6-mercaptopurine,);
 - o Has tried or is currently taking corticosteroids; OR
 - o Has a contraindication to corticosteroid therapy;
- Infliximab is prescribed by or in consultation with a gastroenterologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response in at least one objective measure compared to baseline (e.g., fecal markers, serum markers, imaging studies, endoscopic assessment, and/or reduced dose of corticosteroids); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, fatigue, stool frequency, and/or blood in stool).

Ulcerative colitis (UC)

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Meets one of the following:
 - o Has tried or had an intolerance to at least one systemic agent for ulcerative colitis (e.g., vedolizumab, adalimumab, golimumab, azathioprine, 6-mercaptopurine, cyclosporine, tacrolimus, corticosteroid); OR
 - o Has pouchitis and has tried one of the following: an antibiotic (e.g., metronidazole, ciprofloxacin), probiotic, corticosteroid enema (e.g., hydrocortisone enema), or mesalamine enema;
- Infliximab is prescribed by or in consultation with a gastroenterologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response in at least one objective measure compared to baseline (e.g., fecal markers, serum markers, imaging studies, endoscopic assessment, and/or reduced dose of corticosteroids); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, fatigue, stool frequency, and/or rectal bleeding).

Plaque psoriasis (PP)

The individual must meet all of the following criteria for initial authorization:

- Meets one of the following:
 - o Had a 3-month trial of or intolerance to at least one biologic agent;
 - o Had a 3-month trial of or intolerance to at least one traditional systemic agent (e.g., methotrexate, cyclosporine, acitretin); OR
 - o Has a contraindication to methotrexate therapy;
- Is 18 years of age or older;
- Infliximab is prescribed by or in consultation with a dermatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 90 days (*Note: A patient who has received < 90 days of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline in at least one of the following: estimated body surface area affected, erythema, induration/thickness, and/or scale of areas affected by psoriasis;
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, itching and/or burning).

Behcet's disease

The individual must meet all of the following criteria for initial authorization:

- Meets one of the following:
 - o Has ophthalmic manifestations of Behcet's disease;
 - o Had a trial of at least one tumor necrosis factor (TNF) inhibitor (e.g., adalimumab, etanercept); OR
 - o Has tried at least one conventional therapy (e.g., systemic corticosteroids, immunosuppressant, interferon alfa);
- Infliximab is prescribed by or in consultation with one of the following specialists: rheumatologist, dermatologist, ophthalmologist, gastroenterologist, or neurologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 90 days (*Note: A patient who has received < 90 days of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., best-corrected visual acuity if ophthalmic manifestations, serum markers, ulcer depth, number and/or lesion size);
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, improved visual acuity if ophthalmic manifestations).

Graft-versus-host disease (GVHD)

The individual must meet both of the following criteria for initial authorization:

- Has tried at least one conventional systemic treatment for GVHD (e.g., cyclosporine, tacrolimus, mycophenolate mofetil, corticosteroids);
- Infliximab is prescribed by or in consultation with an oncologist, hematologist, or a physician affiliated with a transplant center.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 1 month (*Note: A patient who has received < 1 month of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., normalization of liver function tests, red blood cell count, or platelet count; resolution of fever or rash); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., improvement in skin, oral mucosal, ocular or gastrointestinal symptoms).

Hidradenitis suppurativa

The individual must meet both of the following criteria for initial authorization:

- Has tried one other therapy (e.g., intralesional or oral corticosteroids, systemic antibiotics, isotretinoin);
- Infliximab is prescribed by or in consultation with a dermatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 90 days (*Note: A patient who has received < 90 days of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Hurley staging, Sartorius score, Physician Global Assessment, Hidradenitis Suppurativa Severity Index);
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain or drainage of lesions, nodules, or cysts).

Colitis, indeterminate

The individual must meet all of the following criteria for initial authorization:

- Is 6 years of age or older;
- Has tried one systemic corticosteroids;
- Has tried mesalamine;
- Has tried either azathioprine or 6-mercaptopurine;
- Infliximab is prescribed by or in consultation with a gastroenterologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response in at least one objective measure compared to baseline (e.g., fecal markers, serum markers, imaging studies, endoscopic assessment, and/or reduced dose of corticosteroids); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain, fatigue, stool frequency, and/or rectal bleeding).

Juvenile idiopathic arthritis

The individual must meet all of the following criteria for initial authorization:

- Meets one of the following:
 - o Has tried one other systemic agent for this condition (e.g., adalimumab, etanercept, methotrexate, non-steroidal anti-inflammatory drug [NSAID]); OR
 - o Has aggressive disease;
- Infliximab is prescribed by or in consultation with a rheumatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Physician Global Assessment [MD global], Juvenile Arthritis Disease Activity Score [JDAS], Clinical Juvenile Arthritis Disease Activity Score [cJDAS], Juvenile Spondyloarthritis Disease Activity Index [JSpADA], reduced dosage of corticosteroids, etc.); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., improvement in limitation of motion, less joint pain/tenderness, decreased fatigue, improved function or activities of daily living, etc.).

Pyoderma gangrenosum

The individual must meet all of the following criteria for initial authorization:

- Meets one of the following:
 - o Has tried one systemic corticosteroid (e.g., prednisone, methylprednisolone);
OR
 - o Had a 2-month trial of or intolerance to at least one immunosuppressive agent (e.g., mycophenolate, cyclosporine);
- Infliximab is prescribed by or in consultation with a dermatologist

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 4 months (*Note: A patient who has received < 4 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline in at least one of the following: size, depth, and/or number of lesions;
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain and/or tenderness of affected lesions).

Sarcoidosis

The individual must meet all of the following criteria for initial authorization:

- Has tried at least one systemic corticosteroid;
- Has tried at least one immunosuppressive agent (e.g., methotrexate, azathioprine, leflunomide);
- Infliximab is prescribed by or in consultation with one of the following specialists: pulmonologist, ophthalmologist, cardiologist, neurologist, or dermatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 90 days (*Note: A patient who has received < 90 days of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., lung function, serum markers, improvement in rash or skin manifestations, imaging studies, etc.);
- Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased cough, fatigue, pain, palpitations, and/or shortness of breath).

Scleritis or sterile corneal ulceration

The individual must meet both of the following criteria for initial authorization:

- Has tried one other therapy for this condition (e.g., non-steroidal anti-inflammatory drugs [NSAIDs], methotrexate, cyclosporine, corticosteroids);
- Infliximab is prescribed by or in consultation with an ophthalmologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:

- o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., serum markers [e.g., C-reactive protein, erythrocyte sedimentation rate]); OR
- o Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased eye pain, redness, light sensitivity, tearing, and/or improvement in visual acuity).

Still's disease

The individual must meet all of the following criteria for initial authorization:

- Meets one of the following:
 - o Had a 2-month trial of or intolerance to at least one conventional synthetic disease-modifying antirheumatic drug (DMARD) (e.g., methotrexate); OR
 - o Had a trial of at least one biologic agent (e.g., Actemra, Arcalyst, Ilaris);
- Has tried one corticosteroid;
- Infliximab is prescribed by or in consultation with a rheumatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., resolution of fever, improvement in rash or skin manifestations, improvement or normalization of serum markers, and/or reduced dosage of corticosteroids); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., less joint pain/tenderness, stiffness, or swelling; improved function or activities of daily living).

Spondyloarthritis (SpA), other subtypes

The individual must meet all of the following criteria for initial authorization:

- Meets one of the following:
 - o Has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet AND has tried at least one DMARD (e.g., methotrexate, leflunomide, sulfasalazine); OR
 - o Has axial spondyloarthritis with objective signs of inflammation, defined as at least one of the following: C-reactive protein elevated beyond the upper limit of normal for the reporting laboratory or sacroiliitis reported on magnetic resonance imaging;
- Infliximab is prescribed by or in consultation with a rheumatologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:

- o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., Ankylosing Spondylitis Disease Activity Score (ASDAS) and/or serum markers [e.g., C-reactive protein, erythrocyte sedimentation rate]); OR
- o Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased pain or stiffness, improvement in function or activities of daily living).

Uveitis

The individual must meet both of the following criteria for initial authorization:

- Meets one of the following:
 - o Has tried one of the following therapies: periocular, intraocular, or systemic corticosteroids, or immunosuppressive agent; OR
 - o Had a trial of either an etanercept product (e.g., Enbrel) or an adalimumab product (e.g., Humira);
- Infliximab is prescribed by or in consultation with an ophthalmologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 months (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:
 - o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., best-corrected visual acuity, assesment of chorioretinal and/or inflammatory retinal vascular lesions, etc.); OR
 - o Has experienced an improvement in at least one symptom compared to baseline (e.g., decreased eye pain, redness, light sensitivity, blurred vision, and/or improvement in visual acuity).

Immunotherapy-related toxicities associated with checkpoint inhibitor therapy

The individual must meet all of the following criteria for initial authorization:

- Developed an immunotherapy-related toxicity other than hepatitis (e.g., gastrointestinal system toxicity, inflammatory arthritis, ocular toxicity);
- Developed the immune-related toxicity while receiving a checkpoint inhibitor (e.g., Keytruda, Opdivo, Yervoy, Tecentriq, Bavencio, Imfinzi);
- Has tried one systemic corticosteroid (e.g., methylprednisolone, prednisone);
- Infliximab is prescribed by or in consultation with an oncologist, gastroenterologist, rheumatologist, or ophthalmologist.

The individual must meet all of the following criteria for re-authorization:

- Has been established on Infliximab therapy for at least 6 month (*Note: A patient who has received < 6 months of therapy, or who is restarting therapy with an infliximab product, is reviewed under initial authorization criteria.*);
- Meets one of the following:

- o Has experienced a beneficial clinical response from baseline when assessed by at least one objective measure (e.g., improvement or normalization of serum markers [e.g., C-reactive protein, erythrocyte sedimentation rate], fecal markers, and/or reduced dosage of corticosteroids); OR
- o Has experienced an improvement in at least one symptom compared to baseline (e.g., less joint pain/tenderness, stiffness or swelling, stool frequency; improved function of activities of daily living).

Approval duration (initial):

- GVHD: 1 month
- Plaque psoriasis/Behcet's disease/Hidradenitis suppurativa/Sarcoidosis: 3 months
- Pyoderma gangrenosum: 4 months
- All others: 6 months

Approval duration (renewal):

- GVHD: 3 months
- All others: 12 months

Dosing Recommendations

Infliximab is administered by intravenous infusion for at least 2 hours.

Crohn's disease, ulcerative colitis, indeterminate colitis, plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and pyoderma gangrenosum

The recommended dose is 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Graft-versus-host disease

The recommended dose is up to 10 mg/kg once weekly.

Rheumatoid arthritis

The recommended dose is 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Ankylosing spondylitis, Behcet's disease, sarcoidosis, and spondyloarthritis

The recommended dose is 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks.

Uveitis and immunotherapy-related toxicities associated with checkpoint inhibitor therapy

The recommended dose is up to 10 mg/kg at 0, 2 and 6 weeks, then every 4 weeks.

Juvenile idiopathic arthritis and Still's disease

The recommended dose is up to 6 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Scleritis or sterile corneal ulceration

The recommended dose is up to 10 mg/kg at 0, 2, 6, and 8 weeks.

References

1. Remicade injection [prescribing information]. Horsham, PA: Janssen; October 2021.

2. Inflectra injection [prescribing information]. Lake Forest, IL: Hospira/Pfizer; June 2021.
3. Renflexis injection [prescribing information]. Jersey City, NJ: Samsung Bioepis/Organon; January 2022.
4. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2018;113(4):481-517.
5. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. *Gastroenterology*. 2021;160(7):2496-2508.
6. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80(4):1029-1072.
7. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. *Arthritis Care Res (Hoboken)*. 2019;71(1):2-29.
8. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2021;73(7):1108-1123.
9. Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol*. 2019;(10):1599-1613.
10. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114(3):384-413.
11. Pardi DS, D'Haens G, Shen B, et al. Clinical guidelines for the management of pouchitis. *Inflamm Bowel Dis*. 2009;15(9):1424-1431.
12. Feuerstein JD, Isaac s KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. *Gastroenterology*. 2020;158:1450-1461.
13. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. *Ann Rheum Dis*. 2018;77(6):808-818.
14. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. *Ophthalmology*. 2014;121(3):785-796.
15. The NCCN Hematopoietic Cell Transplantation (HCT) Clinical Practice Guidelines in Oncology (Version 2.2022 – September 28, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 21, 2022.
16. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. *J Am Acad Dermatol*. 2010;62(2):205-217.
17. Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. *Br J Dermatol*. 2003;149:1046-1049.
18. Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. *J Am Acad Dermatol*. 2007;56:624-628.
19. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. *Acta Derm Venereol*. 2009;89(6):595-600.
20. Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. *Aliment Pharmacol Ther*. 2003;18:741-747.
21. Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. *Aliment Pharmacol Ther*. 2003;18:175-181.
22. The NCCN Management of Immunotherapy-Related Toxicities Clinical Practice Guidelines in Oncology (Version 1.2022 – February 28, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed October 21, 2022.
23. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Rheumatol*. 2019;71(6):846-863.
24. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum*. 2013;65(10):2499-2512.
25. Dabade TS, Davis MD. Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet's syndrome). *Dermatol Ther*. 2011;24(2):273-284.
26. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;58(6):2004079.
27. Riera E, Olivé A, Narváez J, et al. Adult onset Still's disease: review of 41 cases. *Clin Exp Rheumatol*. 2011;29(2):331-336.
28. Pouchot J, Arlet JB. Biological treatment in adult-onset Still's disease. *Best Pract Res Clin Rheumatol*. 2012;26(4):477-487.
29. Kontzias A, Efthimiou P. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances. *Drugs*. 2008;68:319-337.

30. Dastmalchi, M, Grundtman, C, Alexanderson, H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. *Ann Rheum Dis.* 2008;67:1670-1677.
31. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis.* 2020;79(1):19-30.
32. Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. *Arthritis Rheumatol.* 2022 Apr;74(4):553-569.